Fed’s Powell opens door to potential rate cuts at Jackson Hole
BILLERICA, Mass. - Bruker Corporation (NASDAQ:BRKR), a scientific instrument manufacturer with a market capitalization of $4.67 billion, announced Tuesday that its Board of Directors has approved a quarterly cash dividend of $0.05 per share on the company’s common stock, representing a 0.65% annual yield.
The dividend will be paid on October 3, 2025, to stockholders of record as of September 23, 2025, according to a press release statement from the scientific instrument manufacturer. The announcement comes as Bruker’s stock trades near its 52-week low of $30, significantly below its peak of $72.94.
Bruker, which specializes in high-performance scientific instruments and analytical solutions used in life sciences and materials research, maintains its regular quarterly dividend program that provides income to shareholders alongside its growth initiatives.
The company develops and manufactures equipment that enables scientists to explore biological and material samples at molecular, cellular, and microscopic levels, with applications spanning from life science research to industrial analysis and semiconductor metrology.
The dividend announcement comes as part of Bruker’s ongoing capital allocation strategy, which balances shareholder returns with investments in its scientific and analytical instrument business.
In other recent news, Bruker Corporation’s second-quarter earnings for 2025 fell short of forecasts, with earnings per share (EPS) reported at $0.32 compared to the expected $0.42. This represented a negative surprise of 23.81%. Additionally, the company’s revenue reached $797.4 million, missing the forecasted $812.81 million by 1.9%. Several analyst firms have adjusted their price targets for Bruker following these results. TD Cowen and Stifel both lowered their price targets to $40 while maintaining a Hold rating, citing weak demand and academic spending, respectively. Meanwhile, JPMorgan reduced its price target to $50 but maintained an Overweight rating, noting Bruker’s relative success despite challenging market conditions. Barclays also lowered its price target to $43, maintaining an Overweight rating, as analysts had anticipated soft order numbers in the second quarter. These developments reflect the mixed reactions from analysts regarding Bruker’s recent performance and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.